Introduction
============

Xanthogranuloma is a rare non-Langerhans histiocytic disorder that is usually associated with systemic disease or blood abnormalities and is particularly uncommon in the orbit.^[@B1]^ Four forms of adult xanthogranulomatous disease of the orbit (AXDO) can be distinguished depending on clinical characteristics and manifestations, i.e., adult-onset xanthogranuloma (AOX), adult-onset asthma and periocular xanthogranuloma (AAPOX), necrobiotic xanthogranuloma (NBX), and Erdheim--Chester disease (ECD). Histopathology findings are similar for all four of these clinical forms of AXDO.^[@B2]^

Adult-onset xanthogranuloma is the least common and benign form that is characterized by an isolated lesion without significant systemic involvement.^[@B2]^ The hallmark of AAPOX is the asthma component. Most patients experience adult-onset asthma within a few months to a few years after onset of the periocular lesion.^[@B3]^ Almost all cases of NBX are accompanied by paraproteinemia, which may be associated with monoclonal gammopathy of undetermined significance, multiple myeloma, plasma cell leukemia, macroglobulinemia, or cryoglobulinemia.^[@B2]^ ECD is multisystemic and affects many organs. Most cases involve bone and the central nervous system, descending aorta, retroperitoneum, liver, and lungs.^[@B2],[@B4]^

The periorbital lesions are treated with systemic corticosteroids, steroid injections, chemotherapy, radiotherapy, or local excision. There is no convincing evidence that any particular treatment yields better results than another. This report describes a patient with orbital xanthogranuloma that was completely resected via a transcranial orbital approach without requiring any systemic treatment.^[@B2],[@B5]^

Case Report
===========

A 52-year-old man was referred to our office by his primary Ophthalmology Department for further evaluation and treatment of the right orbital tumor. He had a 2-year history of progressively worsening lacrimation. Downward displacement of the right eye and diplopia had been gradually worsening during the previous year. Neurologic examination revealed more deterioration of the right eye visual acuity (20/25) than the left (20/12.5). There was no history of lipoma at any anatomic site. An increased triglyceride level (959 mg/dL) was observed; however, leukemia and asthma were denied on admission. Computed tomography (CT) of the orbits revealed proptosis and inferior displacement of the globe of the right eye by a tumor that was revealed as a 30-mm posterolateral soft tissue density mass. The tumor had destroyed the supraorbital bar and superior wall of the orbit. Magnetic resonance imaging revealed a well-demarcated mass in the craniolateral portion of the right orbit that showed mixed intensity on both T~1~- and T~2~-weighted images without contrast enhancement. A whole-body CT scan revealed no tumor masses in addition to the one in the orbit. Electrocardiography, chest radiography, and pulmonary function tests revealed no abnormalities. There were no signs of punched out regions in the long bones on X-ray examination ([Fig. 1](#F1){ref-type="fig"}).

![Preoperative MRI and CT findings. The tumor was demonstrated mixed intensity on T~2~-weighted image (WI) (A and B) and T~1~-WI (C and D) without contrast enhancement. CT coronal (E) and axial (F) images showed a large heterogeneous soft tissue mass involving the posterolateral orbit of the right eye.](nmccrj-6-121-g001){#F1}

A soft and yellowish lobulated mass covered with membranous tissue was observed at the craniolateral portion in the orbit. Part of the orbital roof had been destroyed by the tumor. The tumor was completely resected via a transcranial orbital approach. Removal of the tumor resulted in a defect of the supraorbital bar. The orbital bar and roof were reconstructed using autogenous frontal and parietal bone ([Fig. 2](#F2){ref-type="fig"}).

![Postoperative MRI and CT findings. T~2~-WI (A), T~1~-WI (B) and CT (C) demonstrated total resection of the tumor. An improvement of downward deviation of the right eye was obtained. The reconstruction of the lateral and superior orbital wall and the supraorbital bar was achieved by the autogenous frontal and parietal bone (D).](nmccrj-6-121-g002){#F2}

Pathologic examination revealed a mixture of inflammatory cells and foam cells with cholesterol clefts. Interstitial fibrosis and multinucleated giant cells were also observed. Immunological staining was positive for CD68 and negative for S100, LCA, and CD1a ([Fig. 3](#F3){ref-type="fig"}). The final pathologic diagnosis was orbital xanthogranuloma.

![Intraoperative findings and Pathological examination. A soft and yellowish lobulated mass covered with the membranous tissue was observed at the craniolateral portion in the orbit, a part of the orbit roof was destructed (A). A mixture of the inflammatory cells, foam cells with cholesterol clefts, a part of interstitial fibrosis and multinucleated giant cells were observed on hematoxylin--eosin stains (B). Immunological staining revealed CD68-positive (C) and S100-negative (D) cells in the tumor.](nmccrj-6-121-g003){#F3}

The displacement of the right eye, and diplopia resolved after the surgery. Lacrimation was subjectively improved. Right eye visual acuity recovered to 20/16. The final diagnosis in our patient was AOX without systemic disease, so no additional treatments were performed. There were no signs of recurrence or systemic disease at follow-up 15 months later.

Discussion
==========

As with most locally growing tumors, surgical removal was deemed the best option for this case of AOX with unilateral orbital involvement. AOX is characterized as local tumor formation in the orbit; this is unlike the other three forms of AXDO that feature systemic disease. Bilateral orbital involvement is generally observed; however, unilateral orbital lesions are also reported, as in our case. Unilateral AOX without systemic disease is considered a good candidate for surgical resection, and therefore avoids steroids and chemotherapeutic agents. In most patients with AXDO, a steroid is used because systemic disease is common. A literature review revealed 12 patients with AOX who had been treated surgically, including our case ([Table 1](#T1){ref-type="table"}).^[@B1],[@B5]--[@B8]^ Patient age ranged from 23 to 79 years, and sex distribution was equal. Four patients (33%) had bilateral involvement. Four patients (33%) had hypercholesterolemia or hypertriglyceridemia. All four types of AXDO may be associated with dyslipidemia;^[@B2]^ however, AOX is only rarely associated with serious systemic findings.

###### 

Surgical cases of adult-onset xanthogranuloma in the orbit

  Author, Year           Age/Sex      Laterality                                              Systemic findings                           Treatment            Follow-up                           Recurrence                         Outcome               
  ---------------------- ------------ ------------------------------------------------------- ------------------------------------------- -------------------- ----------------------------------- ---------------------------------- ----------- --------- -------
  Zeynel et al., 2003    23/F         Bilateral                                               Hypercholesteremia                          Total (1^st^ Tx)     N/A                                 Radiation, Steroid (1^st^ Tx)      8 years     Without   Alive
  41/F                   Unilateral   Hypercholesteremia                                      Total                                       N/A                                                      6 years                            Without     Alive     
  79/F                   Unilateral   Hyperglyceridemia, hyperparathyroidism, hypercalcemia   Partial                                     N/A                                                      12 months                          Without     Alive     
  38/F                   Bilateral    None                                                    Partial (1^st^ Tx)                          N/A                  Steroid (1^st^ Tx)                  10 years                           With        Alive     
  Radiation (2^nd^ Tx)                                                                                                                                                                                                                                      
  79/M                   Unilateral   N/A                                                     Total                                       N/A                                                      Lost to follow-up                                        
  Ramesh et al., 2007    47/M         Unilateral                                              None                                        Total                The medial transcaruncular                                             30 months   Without   Alive
  Shimizu et al., 2010   52/F         Unilateral                                              None                                        Total                Anterior through the lower eyelid                                      2 years     Without   Alive
  Kiratli et al., 2015   29/M         Bilateral                                               Autoimmune sialadenitis, microproteinuria   Partial (1^st^ Tx)   N/A                                 Steroid (1^st^ Tx)                 29 months   Without   Alive
  55/M                   Bilateral    Retinitis pigmentosa, hypertension, type 2 diabetes     Partial (1^st^ Tx)                          N/A                  Steroid (2^nd^ Tx)                  23 months                          Without     Alive     
  57/M                   Unilateral   Hilar lymphadenopathies, *β*2 microproteinuria          Partial (1^st^ Tx)                          N/A                  Steroid (2^nd^ Tx)                  62 months                          Without     Alive     
  Michael et al., 2017   47/F         Unilateral                                              None                                        Partial (1^st^ Tx)   N/A                                 Steroid, methotrexate (2^nd^ Tx)   8 years     With      Alive
  Partial (2^nd^ Tx)                                                                                                                                                                                                                                        
  Tamada et al., 2018    52/M         Unilateral                                              Hypercholesteremia, hyperglyceridemia       Total                Trancranial                                                            8 months    Without   Alive

Tx: Treatment.

A transcranial orbital approach was used in our patient to obtain a wide operative field that would allow total resection of the orbital xanthogranuloma. Six of the 12 reported patients underwent total resection. However, there was no report of orbital xanthogranuloma being treated by transcranial surgical resection. Five (83%) of the six patients who underwent total resection survived without recurrence. The remaining one patient was lost to follow-up. Seven patients underwent partial resection as the first or second treatment, and five (71%) of them needed additional treatment. Two (28%) of these seven patients had recurrent lesions during 8--10 years of follow-up. The remaining five patients survived without recurrence over 12--62 months of follow-up. The two patients who developed recurrence underwent additional treatment with steroids, radiation, or methotrexate. Partial resection (including biopsy) is rarely recommended for treatment of AXDO because of the risk of early relapse after surgery (in \<1 year in the most cases).^[@B2]^ Total resection using a transcranial orbital approach allows a wide and shallow surgical field and is a valid treatment for orbital xanthogranuloma in the absence of severe systemic disease. In addition, there are no cosmetic concerns due to incising in the hair. There is also the merit that autogenous bone can be collected for reconstruction, as in our case. Tumor resection might be expected to increase the likelihood of long-term survival without recurrence.

No adjuvant therapy was required in the present case. The most common treatment used to obtain local control of the disease is systemic steroid therapy. Administration of a steroid has been reported to be an effective treatment option for AXDO with systemic complications. However, this strategy might have temporal effects. Moreover, some patients have not responded to systemic corticosteroids.^[@B2],[@B3]^ Multimodality treatment, such as a combination of systemic steroids with chemotherapy, radiotherapy, and surgery, is now recommended.^[@B2]^ Radiation to the orbit in combination with systemic corticosteroids has proven successful in some cases of AXDO, although exacerbation of cutaneous lesions has been reported.^[@B2]^ Chemotherapy using methotrexate may be efficacious when systemic corticosteroids alone have failed.^[@B3]^ Additional studies are required to establish a standard therapy for orbital xanthogranuloma.

No recurrence was observed in our patient after 15 months of follow-up. All of the 12 reported cases remained alive after follow-up periods ranging from 12 months to 10 years (mean 4.0 years). Screening for systemic disease and long-term follow-up are necessary, even in patients with AOX, because late-onset hematologic malignancies can occur. In past reports, the interval to development of a hematologic malignancy varied from 1 to 25 years after the onset of orbital xanthogranuloma.^[@B9],[@B10]^
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